Avatrom
Generic Name
Avatrombopag
Manufacturer
Acme Pharmaceuticals
Country
Bangladesh
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| avatrom 20 mg tablet | ৳ 260.00 | ৳ 2,600.00 |
Description
Overview of the medicine
Avatrombopag is an oral thrombopoietin receptor agonist indicated for increasing platelet counts in adults with chronic immune thrombocytopenia or chronic liver disease scheduled for a procedure.
Uses & Indications
Dosage
Adults
For CLD: 40 mg or 60 mg once daily for 5 days, starting 10 to 13 days prior to a procedure. For ITP: Initial dose of 20 mg once daily; dose adjusted based on platelet response to achieve and maintain a platelet count ≥50 x 10^9/L. Maximum 60 mg/day.
Elderly
No specific dose adjustment generally needed.
Renal_impairment
No dose adjustment needed.
How to Take
Oral, with food.
Mechanism of Action
Avatrombopag is an oral, small-molecule thrombopoietin (TPO) receptor agonist. It stimulates the proliferation and differentiation of megakaryocytes from bone marrow progenitor cells, leading to an increased production of platelets.
Pharmacokinetics
Onset
1-2 weeks for significant platelet increase.
Excretion
Primarily fecal.
Half life
Approximately 19-20 hours.
Absorption
Well absorbed, peak plasma concentration reached in 4-6 hours.
Metabolism
Primarily via CYP2C9 and CYP3A4.
Side Effects
Contraindications
- Hypersensitivity to avatrombopag or any components of the formulation.
Drug Interactions
Other TPO-RAs
Avoid co-administration.
CYP2C9/3A4 Inhibitors/Inducers
Dose adjustment may be necessary.
Storage
Store below 30°C, protect from light and moisture.
Overdose
Supportive care. No specific antidote.
Pregnancy & Lactation
Use only if potential benefit outweighs potential risk to fetus. Unknown if excreted in human milk; avoid or discontinue drug/nursing.
Side Effects
Contraindications
- Hypersensitivity to avatrombopag or any components of the formulation.
Drug Interactions
Other TPO-RAs
Avoid co-administration.
CYP2C9/3A4 Inhibitors/Inducers
Dose adjustment may be necessary.
Storage
Store below 30°C, protect from light and moisture.
Overdose
Supportive care. No specific antidote.
Pregnancy & Lactation
Use only if potential benefit outweighs potential risk to fetus. Unknown if excreted in human milk; avoid or discontinue drug/nursing.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
24 months
Availability
Pharmacies, Hospitals
Approval Status
Approved by major regulatory bodies (e.g., FDA)
Patent Status
Patented (for the innovator drug)
Clinical Trials
Multiple Phase 3 trials (e.g., ADAPT-1, ADAPT-2, ADVANCE) demonstrated efficacy and safety in patients with chronic liver disease and chronic immune thrombocytopenia.
Lab Monitoring
- Complete blood count (CBC) with platelet count
- Liver function tests
Doctor Notes
- Monitor platelet counts closely before and during treatment.
- Adjust dose to maintain target platelet levels and minimize thrombotic risk.
Patient Guidelines
- Take exactly as prescribed.
- Report any unusual bruising or bleeding.
- Do not stop the medication without consulting a doctor.
Missed Dose Advice
Take the missed dose as soon as remembered. If it is almost time for the next dose, skip the missed dose. Do not double the dose.
Driving Precautions
May cause dizziness; caution advised.
Lifestyle Advice
- Maintain regular follow-up appointments.
- Avoid activities that may increase risk of bleeding (e.g., contact sports).
Alternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine. Click a brand to search for detailed information.